, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, 

 covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with Paul J. Shaughnessy, MD, about the FDA approval of obecabtagene autoleucel (obe-cel; Aucatzyl) for patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). Dr Shaughnessy is the medical director of the Adult Blood and Marrow Stem Cell Transplant Program at Methodist Hospital in San Antonio, Texas.

 for the treatment of adult patients with relapsed or refractory B-cell precursor ALL. This regulatory decision was supported by findings from the phase 1/2 FELIX trial (NCT04404660), in which 42% (95% CI, 29%-54%) of efficacy-evaluable patients with relapsed or refractory CD19-positive B-cell ALL who received the CAR T-cell product achieved a complete response (CR) within 3 months. The median duration of CR achieved within 3 months was 14.1 months (95% CI, 6.1-not reached).

In our exclusive interview, Dr Shaughnessy discussed the significance of this approval, key efficacy and safety findings from the pivotal FELIX trial, and where obe-cel currently fits into the ALL treatment paradigm.

That’s all we have for today! Thank you for listening to this episode of 

. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

 is also on social media. On X, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

, please consider subscribing to our podcast on Apple Podcasts, Spotify, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

*OncLive On Air is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Podcasts

Dr Shaughnessy discusses the significance of the FDA approval of obe-cel for patients with relapsed or refractory B-cell precursor ALL.

FDA Approval Insights: Obe-Cel in B-Cell Precursor ALL

Paul J. Shaughnessy, MD, hematologist, oncologist, medical director, the Adult Blood and Marrow Transplant Program, the Methodist Hospital, discusses the potential of the phase 1/2 FELIX trial (NCT04404660) to address unmet needs in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).

The study is evaluating the safety and efficacy of the CAR T-cell therapy obecabtagene autoleucel (obe-cel) in adult patients with relapsed/refractory B-ALL. Data from the trial showed that at a median follow-up of 6.4 months, obe-cel elicited an overall response rate of 70% in this population. Moreover, obe-cel may offer an improved safety profile compared with other available therapies, according to Shaughnessy, who adds that acceptable rates of cytokine release syndrome (CRS) and neurotoxicity were reported.

Although CAR T-cell therapies are available for patients with relapsed/refractory B-ALL, delivering this option to all patients remains a challenge, Shaughnessy says. Due to the need to travel long distances to treatment centers, obtain a caregiver, and spend time in the hospital, this modality remains inaccessible for a portion of the population. Developing CAR T-cell therapies with lower rates of CRS and other adverse effects could make the modality more accessible to patients and help address that unmet need, Shaughnessy concludes.

Videos

Paul J. Shaughnessy, MD, discusses the potential of the phase 1/2 FELIX trial  to address unmet needs in relapsed/refractory B-cell acute lymphoblastic leukemia.

Dr. Shaughnessy on the Potential of the FELIX Trial to Address Unmet Needs in B-ALL

Paul J. Shaughnessy, MD, hematologist, oncologist, and medical director of Adult Blood and Marrow Transplant Program at the Methodist Hospital, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

The biggest challenge seen with CAR T-cell therapy is that the patients who need this treatment can be very sick; if they have relapsed/refractory disease, it can be rapidly growing, says Shaughnessy. Some of these patients do not have time to have their own lymphocytes collected, genetically engineered, and grown into these CAR T cells.

As such, these patients might not be able to receive treatment with this modality in a timely manner, according to Shaughnessy. However, efforts are being made to overcome this challenge. Experimental methods are being used to develop CAR T-cell therapy from allogeneic donors, allowing the CAR T-cells to be available off the shelf or in a more rapidly accessible; this would allow for more patients to receive treatment more quickly.

Also, many patients with these very advanced cancers will relapse, this needs to be addressed by making better CAR T-cell therapies, says Shaughnessy. Different strategies to achieve this may include making the CAR T cells target 2 antigens instead of just 1, augmenting the therapy with other agents that may increase the immune response, or using radiation to treat relapses before or after the treatment. The field is going to see many advances made in the future, making these therapies more readily available and more effective in patients with hematologic malignancies, concludes Shaughnessy.

Paul J. Shaughnessy, MD, discusses the challenges faced with CAR T-cell therapy in hematologic malignancies.

Dr. Shaughnessy on Addressing Challenges With CAR T-Cell Therapy in Hematologic Malignancies

Paul J. Shaughnessy, MD, hematologist, oncologist, and medical director of Adult Blood and Marrow Transplant Program, at the Methodist Hospital, discusses challenges with CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Often, patients who require CAR T-cell therapy have experienced multiple relapses, are refractory to available treatments, and have rapidly growing disease, says Shaughnessy. Moreover, in some cases, patients are unable to wait for their lymphocytes to be collected, engineered, and grown into CAR T cells.

Improving time-to-treatment with CAR T-cell therapy is an area of significant development, adds Shaughnessy. For example, allogeneic CAR T cells are a potential off-the-shelf option that would allow the product to be offered more readily.

Another challenge is preventing patients from relapsing following CAR T-cell therapy, Shaughnessy says. Some potential strategies to increase the durability of the therapy include dual-targeting antigens and augmenting CAR T with immunotherapy or radiation.

Paul J. Shaughnessy, MD, discusses challenges with CAR T-cell therapy in relapsed/refractory hematologic malignancies.  



Dr. Shaughnessy on Challenges With CAR T-Cell Therapy in Hematologic Malignancies 

Paul J. Shaughnessy, MD, hematologist, oncologist, and medical director of Adult Blood and Marrow Transplant Program, at the Methodist Hospital, discusses the promising future of CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Patients with relapsed/refractory disease have always been a difficult-to-treat patient population, says Shaughnessy, who adds that it may be beneficial to move effective therapies into earlier-line settings.

To date, ongoing randomized studies are comparing the safety and efficacy of CAR T-cell therapy with other standards of care in both non-Hodgkin’s lymphoma and multiple myeloma.

Many are hopeful that, over time, these trials will transform the armamentarium in hematologic oncology, allowing patients to be treated more effectively with fewer adverse effects, Shaughnessy concludes.

Paul J. Shaughnessy, MD, discusses the promising future of CAR T-cell therapy in relapsed/refractory hematologic malignancies.

Dr. Shaughnessy on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

Paul J. Shaughnessy, MD, hematologist, oncologist, and medical director of Adult Blood and Marrow Transplant Program at the Methodist Hospital, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

CAR T-cell therapy ​has demonstrated encouraging activity in adults with relapsed/refractory non-Hodgkin lymphoma and pediatric patients with relapsed/refractory acute lymphoblastic leukemia, says Shaughnessy

​Several ongoing studies are​ evaluating CAR T-cell therapy ​in multiple myeloma and other ​types of lymphoma, explains Shaughnessy. Moreover, the encouraging results observed thus far ​suggest that CAR T-cell therapy will receive regulatory approval in additional indications in the future.

Beyond the hematologic space, CAR T-cell therapy could ​have utility in solid tumors, Shaughnessy concludes.

Paul J. Shaughnessy, MD, discusses the emergence of CAR T-cell therapy in hematologic malignancies.

Dr. Shaughnessy on the Emergence of CAR T-Cell Therapy in Hematologic Malignancies

Paul J. Shaughnessy, MD, hematologist, oncologist, and medical director of Adult Blood and Marrow Transplant Program at the Methodist Hospital, discusses the available CAR T-cell therapies for relapsed/refractory hematologic malignancies.

There are 2 CAR T-cell products that are commercially available now, says Shaughnessy: axicabtagene ciloleucel (axi-cel; Yescarta) and tisagenlecleucel (Kymriah). These products are available for adults with relapsed/refractory diffuse large B-cell lymphoma who have failed all standard therapies. There has been a gap in the availability of treatment for these patients.

CAR T-cell therapies now provide very meaningful responses in these patients, some of which have been very durable for a number of months, or even years. CAR T-cell therapies are very important in filling this gap in patients with relapsed/refractory lymphoma, as well as in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. Once again, there is no standard therapy for this population, though CAR T-cell therapy is offering durable remissions in a percentage of these patients, concludes Shaughnessy.

Paul J. Shaughnessy, MD, discusses the available CAR T-cell therapies for relapsed/refractory hematologic malignancies.

Dr. Shaughnessy on Available CAR T-Cell Therapies in R/R Hematologic Malignancies

Paul J. Shaughnessy, MD, medical director of adult blood and marrow transplant at the Texas Transplant Institute, discusses unanswered questions in the field of diffuse large B-cell lymphoma (DLBCL).

One challenge lies in treating patients with relapsed/chemotherapy-sensitive DLBCL, says Shaughnessy. The ideal scenario would be treating these patients with more effective regimens that result in less toxicity. Then, the question will become whether or not physicians can mobilize a patient’s stem cells with cytokine-alone mobilization techniques to spare patients from toxicity.

In addition to these challenges, physicians are investigating ways of optimizing methods of peripheral blood stem cell transplantation in addition to developing better preoperative regimens. Moreover, research has turned to ways of inducing faster outcomes, such as using higher graft numbers to get quicker outcomes and manipulating the autologous stem cell graft with higher lymphocyte counts. These are all aspects of care that need to be answered in future prospective studies, says Shaughnessy.

Dr. Shaughnessy Discusses Unanswered Questions in DLBCL

Paul J. Shaughnessy, MD, medical director of adult blood and marrow transplant at the Texas Transplant Institute, discusses stem cell mobilization in patients with lymphomas.

There are a variety of chemotherapy agents available to treat patients with different types of lymphoma, and physicians can still mobilize adequate stem cells, even with the newer chemotherapy regimens being used.

Physicians should also be aware of the risk of toxicity to underlining hematopoietic stem cells and not being able to collect adequate number of stem cells.

More studies are necessary, according to Shaughnessy, to better understand if enough stem cells are being given to patients and if this will impact patients better in the future.

2019 Transplantation and Cellular Therapy Meetings

Paul J. Shaughnessy, MD, discusses stem cell mobilization in patients with lymphomas.

Paul J. Shaughnessy, MD

Articles